Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.

Lucy CampbellBirgit BarbiniKeith BurlingBen CromartyLisa HamzahMargaret JohnsonRachael JonesAmanda SamarawickramaDeborah WilliamsAlan WinstonFrank A Postnull null

Published in: Journal of acquired immune deficiency syndromes (1999) (2021)

In individuals with a history of PRT on TDF, 96 weeks of TAF was not associated with recurrent PRT or adverse effects on renal tubular function, bone turnover, or BMD. These data suggest that TAF is a treatment option for this vulnerable population.

Keyphrases

antiretroviral therapy
bone mineral density
hiv infected
hiv positive
human immunodeficiency virus
hiv aids
hepatitis c virus
hiv testing
postmenopausal women
men who have sex with men
emergency department
machine learning
bone loss
bone regeneration